ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Dr. Falk Pharma, Ipsen and Teva Pharmaceutical Industries side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Dr. Falk Pharma×Ipsen×Teva Pharmaceutical Industries×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Dr. Falk PharmaIpsenTeva Pharmaceutical Industries
studies on the registry39358671
open to participants now3266
phase 3 studies under way3162
reach primary completion within a year3153
programswith a study of their own in two years294

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseDr. Falk PharmaIpsenTeva Pharmaceutical Industries
Phase 100%

Ipsen: 1 of its 9 programs at phase 1

  1. tovorafenibphase 1
11%
00%
Phase 2

Dr. Falk Pharma: 1 of its 2 programs at phase 2

  1. vilagletistatphase 2
50%
44%

Teva Pharmaceutical Industries: 1 of its 4 programs at phase 2

  1. emrusolminphase 2
25%
Phase 3

Dr. Falk Pharma: 1 of its 2 programs at phase 3

  1. nor-ursodeoxycholic acidphase 3
50%

Ipsen: 4 of its 9 programs at phase 3

  1. corabotasephase 3
  2. elifibranorphase 3
  3. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3
  4. Palovarotenephase 3
44%

Teva Pharmaceutical Industries: 2 of its 4 programs at phase 3

  1. TEV-53408phase 3
  2. tapinarofphase 3
50%
Approved, new studies00%00%

Teva Pharmaceutical Industries: 1 of its 4 programs at approved, new studies

  1. deutetrabenazineapproved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Dr. Falk Pharma2 readouts · 1 phase 3·········

Dr. Falk Pharma, Aug ’27: 1 program whose next study reaches primary completion

  1. vilagletistatphase 2 · Aug 0 · NCT07298343

Dr. Falk Pharma, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nor-ursodeoxycholic acidphase 3 · Sep 0 · NCT06886360
·
Ipsen3 readouts · 1 phase 3·

Ipsen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. elifibranorphase 3 · Dec 17 · NCT06730061
··

Ipsen, Mar ’27: 1 program whose next study reaches primary completion

  1. corabotasephase 3 · Mar 26 · NCT06937931
······

Ipsen, Oct ’27: 1 program whose next study reaches primary completion

  1. Anti-BTN3A Agonistic Monoclonal Antibody ICT01phase 3 · Oct 15 · NCT04243499
Teva Pharmaceutical Industries1 readouts · 0 phase 3··

Teva Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion

  1. emrusolminphase 2 · Jan 15 · NCT07674940
·········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Dr. Falk Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Ipsen

New programs 1

  • IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Teva Pharmaceutical Industries

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionDr. Falk PharmaIpsenTeva Pharmaceutical Industries
Non-alcoholic Fatty Liver Disease2 of 3 · compare here

Dr. Falk Pharma in Non-alcoholic Fatty Liver Disease: 2 programs

  1. nor-ursodeoxycholic acidphase 3
  2. vilagletistatphase 2

Their studies: Dr. Falk Pharma’s studies of Non-alcoholic Fatty Liver Disease in search

Ipsen in Non-alcoholic Fatty Liver Disease: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Non-alcoholic Fatty Liver Disease in search

–
Celiac Disease2 of 3 · compare here

Dr. Falk Pharma in Celiac Disease: 1 program

  1. vilagletistatphase 2

Their studies: Dr. Falk Pharma’s studies of Celiac Disease in search

–

Teva Pharmaceutical Industries in Celiac Disease: 1 program

  1. TEV-53408phase 3

Their studies: Teva Pharmaceutical Industries’ studies of Celiac Disease in search

Cholangitis, Sclerosing2 of 3 · compare here

Dr. Falk Pharma in Cholangitis, Sclerosing: 1 program

  1. nor-ursodeoxycholic acidphase 3

Their studies: Dr. Falk Pharma’s studies of Cholangitis, Sclerosing in search

Ipsen in Cholangitis, Sclerosing: 1 program

  1. elifibranorphase 3

Their studies: Ipsen’s studies of Cholangitis, Sclerosing in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Dr. Falk Pharma 0 of 2 · Ipsen 4 of 9 · Teva Pharmaceutical Industries 2 of 4 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.